Saturday 24 May 2025

08.00-09.00

Registration

 

 

Electrochemotherapy in Veterinary Oncology: Mechanisms, Applications, and Emerging Therapies

 

09.00-09.45

Electrochemotherapy in Human Oncology: From cutaneous primary and metastatic tumors to emerging applications in solid tumors

Victor Farricha

09.45-10.30

Electrochemotherapy and Immunotherapy: Mechanisms, Immunogenic Potential, and Emerging Combinations in Human and Veterinary Oncology

Maja Cemazar

 

10.30-11.00

 

Coffee break 

 

11.00-11.45

Electrochemotherapy in Veterinary Oncology: Practical Applications and Treatment Optimization

Natasa Tozon

11.45-12.30

Electroporation-Based Therapies in non-cutaneous tumours

Matias Tellado

12.30-13.00

Panel discussion

Speaker Panel

13.00-14.30

Lunch boxes will be provided

 

 

Resident abstracts

 

14.30-14.42

Anti-PD1 and Intratumoral GD2-directed IL2 Immunocytokine-Augmented Radiation-Induced In Situ Vaccination Combination Immunotherapy in Companion Dogs with Malignant Melanoma

 David Vail
 14.42-14.54

Evaluating the impact of elective nodal irradiation for dogs with oral malignant melanoma undergoing hypofractionated radiotherapy

Patricia Gualtier

 14.54-15.06

Pharmacokinetics and Safety of Lysine-Specific Histone Demethylase-1 Inhibitor SP-2577 for Feline Oral Squamous Cell Carcinoma

Jenna Burton

 15.06-15.18

Evaluation of a therapeutic vaccine against the tumor vascular marker versican in dogs with invasive urothelial cell carcinoma

Lobke van Bergen

15.18-15.30

Early detection of cancer using circulating tumor DNA in liquid biopsies: a first step to improve clinical care of Histiocytic Sarcoma through the follow-up of 30 Bernese Mountain Dogs

Benoit Hedant

15.30-16.00

Coffee break

 

16.00-16.30

Sponsored talk by DeepScan

DeepScan CFD test for cancer treatment monitoring
This session will discuss use cases for DeepScan’s new CFD test with focus on cancer treatment monitoring.

 

 

Dr. Katja Kivinen

 

General abstracts

 

 16.30-16.42

 Characterization of somatic mutations in lymphomas of Bernese Mountain dogs

 Valentina Granziera

 16.42-16.54

Survival outcomes of dogs diagnosed with urethral carcinoma treated with high-dose-rate iridium-192 brachytherapy and NSAIDs, NSAIDs alone or no treatment

Jean-Baptiste Eon

 16.54-17.06

Staging Findings in Feline Radiotherapy Candidates: Incidence and Impact on Treatment Decisions

Ian Lee

 17.06-17.18

Reirradiation of recurrent canine intracranial tumors

Maximilian Körner

 17.18-17.30

IL-12/IL-23 as Serum Biomarkers to Measure Response and Prognosis in Canine Lymphoma

Felicia Westling

 

20.00

 

Gala Dinner
Supported by Hill's